SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-017476
Filing Date
2024-01-29
Accepted
2024-01-29 08:14:33
Documents
14
Period of Report
2024-01-29
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d103474d8k.htm   iXBRL 8-K 24898
  Complete submission text file 0001193125-24-017476.txt   143159

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240129.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240129_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240129_pre.xml EX-101.PRE 10816
16 EXTRACTED XBRL INSTANCE DOCUMENT d103474d8k_htm.xml XML 3574
Mailing Address 738 MAIN STREET UNIT 398 WALTHAM MA 02451
Business Address 738 MAIN STREET UNIT 398 WALTHAM MA 02451 617-995-0900
AILERON THERAPEUTICS INC (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 24570257
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)